CN111432817B - 抑制肿瘤移转的方法 - Google Patents

抑制肿瘤移转的方法 Download PDF

Info

Publication number
CN111432817B
CN111432817B CN201880077049.3A CN201880077049A CN111432817B CN 111432817 B CN111432817 B CN 111432817B CN 201880077049 A CN201880077049 A CN 201880077049A CN 111432817 B CN111432817 B CN 111432817B
Authority
CN
China
Prior art keywords
ifetroban
pharmaceutically acceptable
metastasis
cancer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880077049.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111432817A (zh
Inventor
J·M·普利
R·R·拉维耶里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to CN202311091198.4A priority Critical patent/CN117122687A/zh
Publication of CN111432817A publication Critical patent/CN111432817A/zh
Application granted granted Critical
Publication of CN111432817B publication Critical patent/CN111432817B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880077049.3A 2017-11-29 2018-11-29 抑制肿瘤移转的方法 Active CN111432817B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311091198.4A CN117122687A (zh) 2017-11-29 2018-11-29 抑制肿瘤移转的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592365P 2017-11-29 2017-11-29
US62/592,365 2017-11-29
PCT/US2018/062967 WO2019108736A1 (en) 2017-11-29 2018-11-29 Methods of inhibiting tumor metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311091198.4A Division CN117122687A (zh) 2017-11-29 2018-11-29 抑制肿瘤移转的方法

Publications (2)

Publication Number Publication Date
CN111432817A CN111432817A (zh) 2020-07-17
CN111432817B true CN111432817B (zh) 2023-10-31

Family

ID=66664589

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880077049.3A Active CN111432817B (zh) 2017-11-29 2018-11-29 抑制肿瘤移转的方法
CN202311091198.4A Pending CN117122687A (zh) 2017-11-29 2018-11-29 抑制肿瘤移转的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311091198.4A Pending CN117122687A (zh) 2017-11-29 2018-11-29 抑制肿瘤移转的方法

Country Status (9)

Country Link
US (4) US11471444B2 (https=)
EP (1) EP3716973A4 (https=)
JP (1) JP7305197B2 (https=)
KR (1) KR102687556B1 (https=)
CN (2) CN111432817B (https=)
AU (1) AU2018375378A1 (https=)
CA (1) CA3082839A1 (https=)
TW (1) TW201924719A (https=)
WO (1) WO2019108736A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220164000A (ko) * 2020-03-31 2022-12-12 어플라이드 메디칼 테크놀로지스 엘엘씨 Pgd2/dp2 및 트롬복산 a2/tp 수용체의 이중 길항제 및 이상 면역 반응 또는 혈전성 체질의 치료를 위한 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
CN1082043A (zh) * 1992-06-18 1994-02-16 E.R.斯奎布父子公司 适用于制备抗血栓形成和抗血管痉挛的化合物7-氧杂双环庚基取代的噁唑酰胺前列腺素类似物中间体的制备方法
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
WO2009089098A1 (en) * 2008-01-03 2009-07-16 Musc Foundation For Research Development Methods for the treatment of cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066480A (en) 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
US4839384A (en) 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
US5153327A (en) 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
ZA911453B (en) 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5158967A (en) * 1991-06-12 1992-10-27 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5260449A (en) 1992-08-12 1993-11-09 E. R. Squibb & Sons, Inc. Method for preparing 7-oxabicycloheptyl substituted bromooxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
US5332840A (en) 1993-05-27 1994-07-26 Bristol-Myers Squibb Company Method for preparing a benzaldehyde intermediate
US5605917A (en) 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
IL137937A0 (en) 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
EP1986675A2 (en) 2006-02-24 2008-11-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
US20080160024A1 (en) 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
US9283266B2 (en) 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8912167B2 (en) 2011-05-19 2014-12-16 Eugene J. Oliva Heparin-based compositions and methods for the inhibition of metastasis
US20170226514A1 (en) 2014-08-13 2017-08-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prevention of tumour metastasis by inhibition of necroptosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
CN1082043A (zh) * 1992-06-18 1994-02-16 E.R.斯奎布父子公司 适用于制备抗血栓形成和抗血管痉挛的化合物7-氧杂双环庚基取代的噁唑酰胺前列腺素类似物中间体的制备方法
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
WO2009089098A1 (en) * 2008-01-03 2009-07-16 Musc Foundation For Research Development Methods for the treatment of cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Abstract3445:Targeting thromboxane A2 receptor（TP） to block breast cancer metastasis;Zhang xuejing. et al;《TUMOR BIOLOGY》;20120415;第3445页 *
Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system;Honn K V;《Clinical and Experimental Metastasis》;19830101;第1卷(第2期);第103-114页 *
Thromboxane A2 Regulation of Endothelial Cell Migration, Angiogenesis, and Tumor Metastasis;Daotai Nie 等;《Biochemical and Biophysical Research Communications》;20000107;第267卷(第1期);第245-251页 *
Zhang xuejing. et al.Abstract3445:Targeting thromboxane A2 receptor（TP） to block breast cancer metastasis.《TUMOR BIOLOGY》.2012,第3445页. *
大卫 莱登.《肿瘤转移 生物学基础与治疗》.复旦大学出版社,2015,第5-8页. *

Also Published As

Publication number Publication date
CN117122687A (zh) 2023-11-28
JP2021504385A (ja) 2021-02-15
EP3716973A1 (en) 2020-10-07
US20250144079A1 (en) 2025-05-08
CN111432817A (zh) 2020-07-17
KR20200093575A (ko) 2020-08-05
AU2018375378A1 (en) 2020-05-28
KR102687556B1 (ko) 2024-07-22
US20240041839A1 (en) 2024-02-08
US11471444B2 (en) 2022-10-18
US20230090578A1 (en) 2023-03-23
WO2019108736A1 (en) 2019-06-06
US20200405694A1 (en) 2020-12-31
JP7305197B2 (ja) 2023-07-10
CA3082839A1 (en) 2019-06-06
EP3716973A4 (en) 2021-11-10
TW201924719A (zh) 2019-07-01

Similar Documents

Publication Publication Date Title
TWI818954B (zh) 三取代之苯并三唑衍生物的使用方法
JP2018533560A (ja) 癌を治療するための併用療法
EP3279201B1 (en) Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
KR102567244B1 (ko) 암을 치료하는 조성물 및 방법
JP6462147B2 (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
RS62136B1 (sr) Kristalne tozilatne soli selektivnog inhibitora pi3k delta za upotrebu u farmaceutskim formulacijama
CN111212643A (zh) 联合疗法
HUP0400024A2 (hu) Neoplasztikus betegségek kezelésére szolgáló gyógyszerkombinációk
US20250144079A1 (en) Methods of inhibiting tumor metastasis
KR102275112B1 (ko) 5-브로모-인디루빈
TW202021592A (zh) 組合療法
TW202021591A (zh) B細胞惡性腫瘤之治療
WO2013107225A1 (zh) N-（（4-氯-3-三氟甲基）苯基）-n'-（2-氟-4-（（2-羟甲基氨基甲酰基)-4-吡啶基氧）苯基）脲及其作为抗癌药物的应用
CN114206896A (zh) 环状脱氧核糖核苷酸化合物
ES2348996T3 (es) Potenciador de radioterapia.
HK40033357A (en) Methods of inhibiting tumor metastasis
WO2021114089A1 (en) Methods of using crocetin in treating solid tumors
KR102959095B1 (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
KR20130012253A (ko) 간세포암 치료를 위한 항종양제 또는 수술 후 보조 화학 요법제
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
HK40063264A (en) Cyclic deoxyribonucleotide compounds
HK1142526A (en) Synergistic combination of anthranilamide pyridinureas and benzamide derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033357

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant